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Abstract
Background—Milk fat globule-epidermal growth factor-factor VIII (MFG-E8) is a secretory
glycoprotein with a known role in inflammation. In sepsis, interleukin-17 (IL-17) acts as a
proinflammatory cytokine to exaggerate systemic inflammation. We hypothesize that MFG-E8
downregulates IL-17 expression in sepsis.
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Methods—Sepsis was induced in 8-week-old male C57BL/6 mice by cecal ligation and puncture
(CLP). Recombinant mouse MFG-E8 (rmMFG-E8) at a dosage of 20 μg/kg body weight or PBS
was concurrently injected. After 10 h, blood and spleen samples were harvested for analysis. For
in vitro studies, splenocytes isolated from healthy mice pre-treated with rmMFG-E8 and
splenocytes from MFG-E8 knockout (mfge8−/−) mice were stimulated with phorbol myristate
acetate (PMA) and ionomycin, followed by measurement of IL-17 expression with either qPCR or
ELISA.
Results—At 10 h after CLP, rmMFG-E8 inhibited the elevated levels of IL-17 protein in serum
by 31%, compared to the vehicle. In the spleen, rmMFG-E8 reduced the upregulated IL-17 mRNA
and protein levels by 81% and 51%, respectively. This correlated with a significant reduction in
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organ injury markers AST and ALT in sepsis after administration of rmMFG-E8. In vitro
treatment of splenocytes isolated from healthy mice with rmMFG-E8 showed significant
downregulation in PMA/ionomycin-induced IL-17 expression. In contrast, CD4 T-cells from
mfge8−/− mice showed significant upregulation of IL-17 compared to wild-type mice. The
phosphorylated level of STAT3 was downregulated in spleen tissue of septic mice treated with
rmMFG-E8. Conversely, mfge8−/− mice showed increased pSTAT3 compared to wild-type mice
after sepsis.
Conclusion—Our findings demonstrate MFG-E8-mediated downregulation of IL-17 expression,
implicating its potential as a novel therapeutic agent against sepsis.

INTRODUCTION
Author Manuscript

Sepsis is a pervasive and constant human health concern that affects approximately 3 million
people in the United States every year 1, 2. Mortality is estimated between 15 % and 30%, at
a cost to our healthcare system for hospital care totaling more than $24 billion each year 2–4.
Injury from sepsis occurs as a result of an exaggerated or uncontrolled inflammatory
response and mortality stems from injuries sustained by the various organ systems.
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Interleukin-17 (IL-17) is a family of cytokines first found to be expressed in activated CD4
T- cells, and includes IL-17A, -B, -C, -D, -E, and -F 5–7. They were initially thought to only
be produced from Th17 cells, but later found to be produced in other immune cells including
neutrophils, lymphocytes, inducible Natural Killer T (iNKT) cells, γδ T cells, and Paneth
cells 5, 6, 8. IL-17A has been linked to severity of inflammation in tissues, and seen to
predominantly interact with endothelial cells, epithelial cells, fibroblasts, and macrophages,
producing proinflammatory mediators such as IL-1β, IL-6, and tumor necrosis factor-α
(TNF-α) 5. IL-17 is involved in varied processes that include bacterial defense, rheumatoid
arthritis, allograft rejection, tumor modulation, and asthma and allergic reactions 9.
Although it is in these latter autoimmune processes that IL-17 has been more widely studied,
IL-17 has recently attracted attention as a regulator of innate immunity in host defense.
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Regulation of IL-17 expression in activated T-cells is mediated via a wide range of
cytokines, including IL-23, transforming growth factor-β1 (TGF-β1), IL-6, IL-1β, and
IL-21 6, 10. Differentiation of IL-17-producing Th17 cells requires a novel set of
transcription factors, including signal transducer and activator of transcription 3 (STAT3),
retinoic acid receptor related orphan receptor γ (RORγ), and nuclear factor kappa B (NFκB) 6, 10. Conversely, IL-10 is well known for suppressing IL-17 expression in Th17 cells
and macrophages 11. Mice deficient in IL-10 will exhibit higher levels of IL-17 due to
STAT3 and RORγ upregulation 11. Similarly, IL-18, an IL-1 family epithelial-derived
cytokine, has recently been shown to regulate IL-17 expression during homeostatic and
inflammatory conditions likely by antagonizing IL-1R1 signaling in Th17 cells 12.
In an experimental model of sepsis using cecal ligation and puncture (CLP), IL-17 was
identified to promote high levels of proinflammatory mediators and bacteremia 9. Levels of
IL-17 rose in a time-dependent manner after CLP, and in vitro incubation of macrophages
with lipopolysaccharide (LPS) and IL-17 increased production of TNF-α, IL-1β, and IL-6 9.
Furthermore, targeting of IL-17 with neutralizing antibodies showed a protective effect, with
Surgery. Author manuscript; available in PMC 2017 February 01.
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reduced bacteremia and increased survival 9. Additionally, neutralization of peritoneal IL-17
after CLP resulted in markedly improved neutrophil infiltration and decreased levels of
proinflammatory cytokines 13.
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We have previously shown that administering recombinant milk fat globule-EGF factor VIII
(MFG-E8) during sepsis provides beneficial effects 14, 15. MFG-E8 is a 66 kDa glycoprotein
that is expressed in nearly all organs and various cell types that include macrophages and
dendritic cells 16. It is strongly expressed in mammary glands, as well as in the spleen,
lungs, liver, lymph nodes, and brain 17, 18. It was initially identified as a major component of
mouse milk fat and is known to play a role in facilitating the phagocytic clearance of
apoptotic cells by professional phagocytes 16, 17. MFG-E8 is secreted from cells and binds to
αvβ3-integrin on phagocytes and exposed phosphatidylserine (PS) on apoptotic cells via its
N- and C-terminal conserved domains, respectively, enhancing phagocytic engulfment of
dead cells 16, 17. Apart from this universal function, a direct, MFG-E8-mediated antiinflammatory role via inhibition of pro-inflammatory cytokines and chemokines has recently
been reported 19, 20. Hence, MFG-E8 is pivotal for maintaining tissue homeostasis by
regulating several cell signaling events, and its deficiency can lead to severe inflammatory
disorders 17, 18, 21, 22. Although beneficial outcomes of MFG-E8 treatment in sepsis and in
other inflammatory disorders have been demonstrated, its molecular mechanism has yet to
be fully elucidated. In this study, we investigated the role of MFG-E8 in decreasing the proinflammatory cytokine, IL-17 in sepsis. Based on our findings, MFG-E8 could serve as a
therapeutic agent in sepsis by reducing IL-17 expression both locally and systemically.

MATERIALS AND METHODS
Animal model of sepsis
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Male 8–10 weeks old C57BL/6 mice (21–28 g) purchased from Taconic (Albany, NY, USA)
were anesthetized with isofluorane and underwent cecal ligation and puncture (CLP) 23.
Briefly, a 1.5 cm incision was made to the abdominal wall, and the cecum exposed and
ligated 0.5 cm from the tip with 4-0 silk suture. A 22-gauge needle was used to make two
punctures through and through to the distal cecum, extruding a small amount of fecal
material. The cecum was replaced into the abdominal cavity, and the abdomen was closed in
two layers with running 6-0 nylon suture. The sham mice underwent the same procedure
with the exception that the cecum was neither ligated nor punctured. Animals were
resuscitated with 1 ml of normal saline subcutaneously.
In vivo administration of recombinant mouse MFG-E8 (rmMFG-E8)
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Immediately after performing CLP, a small incision on the neck was made to expose the
internal jugular vein (IJ). Commercially available recombinant mouse MFG-E8 (rmMFGE8) (Cat. No.: 2805-MF-050; R&D systems, Minneapolis, MN) was delivered by bolus
injection through the IJ vein using 29G × 1/2″ U-100 insulin syringe (Terumo Medical
Corporation, Elkton, MD) at a concentration of 20 μg/kg BW in 100 μl or same volume of
PBS as vehicle. A survival study performed with this model in mice determined the lethal
dose (LD50) to occur at day 7 in the 10 day monitoring period 24. The proximal and distal
ends of the jugular vein were ligated and the wound was closed with one interrupted 4-0
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nylon suture. After wound closure, the mouse was given 500 μl of normal saline (NS)
subcutaneous fluid resuscitation. The animals were allowed food and water ad libitum until
10 hours after the time of intervention and the animals were euthanized. Blood and tissue
samples were collected for various ex vivo analyses. All experiments were performed in
accordance with the guidelines for the use of experimental animals by the National Institute
of Health and were approved by the Institutional Animal Care and Use Committee of The
Feinstein Institute for Medical Research.
Quantitative real-time PCR analysis
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Total RNA was extracted from spleen tissue using TRIzol (Invitrogen; Carlsbad, CA) and
reverse-transcribed into cDNA using murine leukemia virus reverse transcriptase (Applied
Biosystems; Foster City, CA). The PCR reaction was performed in 25 μl of final volume
containing 0.08 μmol of forward and reverse primer, cDNA, and 12.5 μl SYBR Green PCR
Master Mix (Applied Biosystems). The thermal profile used by the Applied Biosystems
7300 real-time PCR machine was: 50°C for 2 min, 95°C for 10 min, 45 cycles of 95°C for
15 seconds, and 60°C for 1 min. Mouse β-actin was used for normalization. Relative
expression of mRNA was represented as fold change in comparison to the sham group. The
primer sequences are: IL-17A (NM_010552): Forward: CAGGGAGAGCTTCATCTGTGT,
Reverse: AGGAAGTCCTTGGCCTCAGT; β-actin (NM_007393): Forward:
CGTGAAAAGATGACCCAGATCA, Reverse: TGGTACGACCAGAGGCATACAG.
Western blot analysis
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Spleen tissue was homogenized in lysis buffer (10 mM Tris-HCl, pH 7.5; 120 mM NaCl;
1% NP-40; 1% sodium deoxycholate; and 0.1% sodium dodecyl sulfate) containing protease
inhibitor (Roche Diagnostics; Indianapolis, IN), then sonicated (Fisher Scientific; Waltham,
MA). Protein concentrations were determined by Bio-Rad protein assay reagent (Hercules,
CA). Total lysate was electrophoresed on SDS-polyacrylamide gels and transferred to
nitrocellulose membranes. The membranes were then blocked with 0.1% casein in 0.2× PBS
and then incubated with anti-IL-17A (Cat. No. ab79056; Abcam, Cambridge, MA),
phosphorylated STAT3 (Tyr705) (Cat. No.: 9131; Cell Signaling Technology, Beverly,
MA), or β-actin (Cat. No.: A2228; Sigma, St. Louis, MO) primary antibodies. After
washing, the membranes were incubated with a fluorescently-labeled secondary antibody
(Cat. No.: 925-68020, 925-32211, LI-COR; Lincoln, NE). The Odyssey image system (LICOR) was used to scan the membranes, and the Odyssey densitometric software used to
measure band intensities.
Analysis of organ injury markers
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Blood samples were centrifuged at 2,000g for 15 min to collect serum and then either
analyzed for injury parameters immediately, or stored at −80°C. Aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) levels were
measured using assay kits from Pointe Scientific (Canton, MI).
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For in vitro studies, the spleen was removed from normal C57BL/6 mice and cell
suspensions were prepared by disruption using frosted glass slides in RPMI medium with
10% FBS. The isolated cell suspensions were then passed through a 70 μm nylon mesh (BD
Falcon, Durham, NC), and red blood cell (RBC) lysis was conducted with RBC lysis
solution (10 mM KHCO3, 150 mM NH4Cl, 0.1 mM EDTA, pH 8.0). After centrifugation at
200g for 10 min, the cell pellets were resuspended in RPMI medium with 10% FBS. A total
of 2.5 × 106 splenocytes were plated and pre-treated with either rmMFG-E8 (500 ng/ml) or
PBS for 90 min. The cells were then stimulated with Phorbol 12-myristate 13-acetate (PMA)
and ionomycin at 10 ng/ml and 1 μg/ml, respectively. After 5 h of PMA/ionomycin
stimulation, cells were collected by centrifugation at 300g followed by mRNA isolation and
cDNA preparation for the measurement of IL-17A expression by qPCR.
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In another in vitro study, a total of 1 × 106 CD4 T-cells/ml isolated from wild-type (wt) and
MFG-E8 knockout (mfge8−/−) mice spleens using mouse EasySep CD4 T-cell isolation kit
(Stem Cell Technologies, Vancouver, Canada) were stimulated by PMA (10 ng/ml) and
ionomycin (1 μg/ml) overnight, followed by the measurement of IL-17 levels in culture
supernatants by enzyme linked immunosorbent assay (ELISA) (eBioscience; San Diego,
CA). Mfge8−/− mice were obtained as a kind gift from Dr. Shigekazu Nagata, Kyoto
University, Japan. They were developed by replacing exons 4–6 of the MFG-E8 gene with a
neomycin cassette. The chimera mice were then backcrossed to C57BL/6 mice at least 9
times to generate mfge8−/− mice 25.
Statistical analysis
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Data are expressed as mean ± standard error of the mean (SEM) and compared via one way
analysis of variance (ANOVA) and Dunn’s and Student-Newman-Keuls (SNK) test for
multiple group comparisons. Student’s t-test and Mann Whitney Rank Sum test were applied
only for a pair comparison. Significance was considered if p ≤ 0.05 between the
experimental groups.

RESULTS
Recombinant MFG-E8 downregulates IL-17A levels in blood after CLP
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IL-17 serves as a pro-inflammatory cytokine and its expression is induced in sepsis 5, 9. To
assess the in vivo effect of rmMFG-E8 on IL-17A production after CLP, serum was
analyzed by western blot. As shown in Figure 1, septic mice treated with vehicle showed a
35% increase in IL-17. Mice treated with intrajugular rmMFG-E8 had significantly
decreased levels of IL-17A protein in the plasma, with approximately 31% inhibition
compared to the vehicle-injected animals.
Downregulation of IL-17A expression in spleen tissue after recombinant MFG-E8
administration into septic animals
The spleen is a major organ for IL-17 expression. In addition to systemic levels of IL-17A,
we wanted to examine local expression. In septic mice, vehicle spleen exhibited a 17-fold
and 68% increase in mRNA and protein expression, respectively, compared to sham.
Surgery. Author manuscript; available in PMC 2017 February 01.
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Compared to the vehicle group, intrajugular treatment of rmMFG-E8 significantly inhibited
IL-17A mRNA and protein expression by 81% and 51%, respectively (Figure 2A, B).
Recombinant MFG-E8 attenuates organ injury in sepsis
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Sepsis causes severe organ injury as reflected by the elevated levels of AST and ALT in
serum. To establish whether rmMFG-E8 has any protective effect against the severity of
sepsis, we performed CLP on C57BL/6 mice and treated them with rmMFG-E8 or vehicle
via intrajugular injection. We then assessed the levels of AST, ALT, and LDH in serum at
10 h after CLP. We found that after sepsis the serum levels of AST, ALT, and LDH were
significantly upregulated 2.2-fold, 2.9-fold, and 2.5-fold respectively (Figure 3A–C). In
contrast, mice treated by rmMFG-E8 significantly downregulated serum AST and ALT
levels by 39% and 43%, respectively, compared to the vehicle-treated CLP animals (Figure
3A, B). For LDH, although we could not attain statistically significance, a considerable
inhibition of about 24% in its levels was evident in rmMFG-E8-treated mice as compared to
that of vehicle-treated septic mice (Figure 3C).
In vitro treatment of recombinant MFG-E8 directly attenuates IL-17A expression in
splenocytes
To evaluate the direct effects of rmMFG-E8, we established an in vitro system. Primary
splenocyes were pre-treated with rmMFG-E8 and then stimulated using PMA/ionomycin,
followed by the assessment of IL-17A expression. PMA and ionomycin are both naturally
isolated compounds that are commonly used together to stimulate intracellular cytokine
production. As shown in Figure 4, in vitro treatment of rmMFG-E8 in splenocytes
significantly downregulated IL-17A expression at its mRNA level by 49% as compared with
the PBS-treated counterpart.

Author Manuscript

Deficiency of endogenous MFG-E8 leads to exaggerated IL-17 expression in vitro
To examine whether MFG-E8 deficiency causes increased IL-17 expression, we cultured
CD4 T-cells isolated from wt or mfge8−/− mice in the presence of PMA/ionomycin and then
assessed IL-17 production in culture supernatants. Of note, we observed significant
upregulation of IL-17 production 4.7-fold from the CD4 T-cells of mfge8−/− mice compared
to wt mice, indicating that loss of MFG-E8 might potentiate IL-17 production during
inflammation (Figure 5).
Activation of STAT3 in the spleen is attenuated in recombinant MFG-E8-treated septic
animals
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To investigate the underlying mechanism of rmMFG-E8-mediated downregulation of IL-17
expression in sepsis, we focused on phosphorylated STAT3 (pSTAT3), a vital transcription
factor for IL-17 expression. Septic animals showed a 4.7-fold increase in level of IL-17
expression in spleen tissue compared to the sham. Animals treated with rmMFG-E8 showed
a 54% inhibition of STAT3 phosphorylation in spleen tissue (Figure 6A).
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To further confirm the role of MFG-E8 in regulating STAT3 in sepsis, we induced CLP in
mfge8−/− mice and analyzed spleen tissue for pSTAT3. As shown in Figure 6B, there is
significant upregulation of pSTAT3 levels in both wt and mfge8−/− mice after CLP as
compared to their respective sham animals, 2.7-fold and 4.8-fold, respectively. There is also
a 25% increase in the level of pSTAT3 protein between the wt and mfge8−/− mice. Together
with Figure 6A, these data support the notion that inhibition of IL-17 expression by
rmMFG-E8 in sepsis is mediated through the downregulation of STAT3 activation.

DISCUSSION

Author Manuscript
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Sepsis is a major clinical problem and a significant burden on resources in our intensive care
units. Even though various treatment modalities have been implicated in reducing sepsisrelated mortality, none have been successful. There has only been one FDA-approved
treatment available on the market, recombinant activated protein C, drotrecogin alfa (Eli
Lilly, Indianapolis, IN), but it was withdrawn due to concerns about safety and questions
about efficacy 26. Clinical trials have also been conducted with the aim to counteract
individual sepsis-inducing inflammatory mediators—for example, tumor necrosis factor
(TNF)-α and interleukin (IL)-1 27. Unfortunately, none of the trials demonstrated any
benefit from treatment 28. Attention has therefore shifted toward targeting novel cytokines
that regulate other pro-inflammatory molecules in response to invading pathogens 29, 30.
IL-17 is an example of a pleiotropic cytokine that interacts with macrophages, epithelial
cells, fibroblasts, and endothelial cells and can initiate production of a wide range of
proinflammatory mediators such as IL-1, TNF-α, IL-6, and IL-8. The strategy of
neutralizing IL-17 is therefore a distinct approach from previous experiments with IL-1 and
TNF-α blockade/inhibitors.
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Originally identified as an important factor for clearance of apoptotic cells, MFG-E8 has
been shown to be beneficial in sepsis 15, 25, 31, 32. It has a role in diverse physiological
functions, including anti-inflammation, tissue regeneration, and clearance of apoptotic cells
to maintain tissue homeostasis, which makes it an important component in various acute and
chronic inflammatory diseases 18. Another protein that also serves as a bridging molecule
for the phagocytosis of apoptotic cells, growth arrest-specific protein 6 (GAS6), has been
shown to downregulate IL-17 in serum and spleen, and be protective in sepsis 33, 34. IL-17 is
known to cause exaggerated inflammation and organ injury during the course of
inflammatory disease, and strategies for targeting IL-17 during experimental sepsis in
rodents were found to be beneficial 5, 6, 9, 35. Direct blockade of IL-17 with intravenously
administered antibody, even at 12 h after a severe model of CLP, improved survival and
decreased systemic proinflammatory mediators and bacteremia 9. Similarly, injection with
anti-IL-17A antibody into the peritoneal cavity of septic mice also showed a survival
advantage 13. In our previous studies, we have shown a significant improvement in survival
with administration of recombinant MFG-E8 in septic rats 32. We have also shown that
mfge8−/− mice had significantly increased mortality compared to wild-type mice after
CLP 24. It is therefore reasonable to explore the potential function of MFG-E8 as another
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scavenging molecule for apoptotic clearance in the downregulation of IL-17 production in
sepsis.
For our model, since other studies have shown that serum levels of IL-17 reached its peak at
around 12 h after CLP, we chose to evaluate the efficacy of rmMFG-E8 for regulating IL-17
expression at 10 h, which is close to the above time point 9, 13. IL-17 levels could also peak
as early as 3 h after CLP, occuring in a case of a more severe model 36. Our study revealed
that there is inhibition of IL-17A expression in blood and spleen tissue of septic mice treated
with rmMFG-E8, and also direct attenuation of IL-17 expression under in vitro conditions.
The outcome of rmMFG-E8-mediated downregulation of IL-17 expression strongly
correlated with decreased levels of organ injury markers. We established a novel link
between MFG-E8 and IL-17 expression during sepsis, and also focused on a new paradigm
for exploring a potential role towards controlling the innate immune system.

Author Manuscript

Our experimental model did not include the use of antibiotics since we were studying the
animals for only a short period of time after non-severe CLP. All the mice survived at time
of harvest at 10 h, though some appeared sick. These mice had severe systemic
inflammation, as shown by elevated levels of pro-inflammatory cytokine IL-17 and injury
markers, ALT, AST, and LDH. Since our current study does not evaluate for survival after
CLP, but instead involves a non-lethal model of CLP to study the pathogenesis of sepsis, we
did not pursue an antibiotic treatment approach.

Author Manuscript

Male mice were chosen for our experiments instead of mixed gender mice because of recent
findings from experimental and clinical studies indicating sex-specific differences in sepsis
and infectious disease 37. Male and female sex steroids exhibit immune-modulating
functions in both humoral and cell-mediated immune responses under normal conditions and
in varied disease processes 37. Experimental studies in mice revealed a significantly
increased survival rate of proestrus female mice following polymicrobial sepsis induced by
CLP compared with male animals 38. Therefore, male and female sex differences may not be
ignored when using animals to study sepsis pathogenesis. To generate reliable and consistent
findings, we only used male mice. Furthermore, specific to the purposes of our study, MFGE8 is a milk-derived glycoprotein that is abundantly expressed and secreted from the
mammary gland of female mice 18. Studies show that the hormone prolactin can induce
MFG-E8 expression during the lactation period of female mice 39, which would be difficult
to adequately control for in an experiment with mixed gender mice.
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Aside from sepsis, MFG-E8 has also been studied in other processes. An indirect role of
MFG-E8 for regulating IL-17 expression has previously been shown in a model for tumor
growth 40. Granulocyte-macrophage colony-stimulating factor (GM-CSF) upregulates MFGE8 via macrophage expression. GM-CSF-deficient macrophages were shown to have
markedly decreased MFG-E8 levels in the spleen, lung, and other tissues, which resulted in
an altered immune cell and cytokine profile 40. Co-culturing GM-CSF deficient
macrophages with naïve T-cells in the presence of apoptotic cells resulted in Th17 skewing
due to impaired phagocytosis of apoptotic cells caused by reduced expression of MFGE8 40.
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Even in chronic inflammatory disease, MFG-E8 deficiency is correlated with increased
IL-17 levels. In a model of periodontitis, loss of MFG-E8 led to increased bone loss which
was associated with elevated levels of IL-17 from excised gingival tissues 41. Similarly, in a
study of an MFG-E8 homolog, Del-1, periodontitis was accompanied by a decrease in Del-1
expression, and associated with an increase in neutrophil infiltration and increased IL-17
expression 42. Knockout mice for Del-1 also showed an increased level of IL-17A and
neutrophils specifically in the lung 42.
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The mechanism of IL-17 expression and its functions have been extensively studied in
recent years 6, 7. STAT3 serves as a potent transcription factor for the expression of a wide
range of pro-inflammatory genes 43. Activated STAT3 has been well reported as a vital
transcription factor for the expression of IL-17 44. STAT3 is phosphorylated at Tyr705
which allows dimerization and translocation to the nucleus as a transcription factor to induce
target gene expression 45. To ascertain a mechanistic pathway for IL-17A upregulation, we
focused on assessing STAT3 activation in terms of Tyr705 phosphorylation and noticed
significantly decreased levels of STAT3 phosphorylation in the spleen of rmMFG-E8treated mice after sepsis. Although the role of MFG-E8 for regulating STAT3 activation was
previously demonstrated in an in vitro system utilizing peritoneal macrophages, its clinical
relevancy was unknown 19. In our model of acute systemic inflammation, we discovered the
negative regulatory role of MFG-E8 for downregulating IL-17 expression in serum and
tissue, and relationship to reducing organ injury markers. Further studies could reveal the
missing novel negative regulators that might control STAT3 activation upon MFG-E8
treatment.
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Apart from the deleterious role of IL-17, there are also some studies that suggest that
IL-17A could be beneficial to the host in sepsis. Studies by Ogiku et al showed that
mortality in sepsis was increased among IL-17 knock-out mice compared to their wt
counterparts 46. Similarly, in other studies involving CLP or K. pneumonia/T. gondiimediated acute inflammatory models, IL-17 receptor (IL-17R) deficient mice had reduced
survival due to reduced neutrophil chemotaxis at the infectious foci to clear the bacterial
load 47, 48. These findings reflect the importance of IL-17/IL-17R axis in host defense
against infection. Obviously, as a component of the innate immune system, IL-17 and its
receptor might be upregulated at a desired level to carry out their designated roles in
responding to infection. Loss of expression of IL-17 or IL-17R with knockout mice might
not be beneficial due to this impaired response against infection. Therefore, a fine-tuned
balance should be emphasized for both host protection and also regulation of the abnormal
induction seen in the septic “cytokine storm.”
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In summary, our study revealed the inhibition of IL-17A expression in blood and spleen
tissue in mice treated with rmMFG-E8 after sepsis, and direct attenuation of IL-17
expression under in vitro conditions. This downregulation of IL-17 expression strongly
correlated with decreased levels of organ injury markers. Therefore, there is a clearly
beneficial role of MFG-E8 in downregulating IL-17 expression via modulating STAT3
activation, implicating its potential as a novel therapeutic agent against sepsis.
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LIST OF ABBREVIATIONS

Author Manuscript

CLP

cecal ligation and puncture

BW

body weight

PBS

phosphate-buffered saline

AST

aspartate aminotransferase

ALT

alanine aminotransferase

LDH

lactate dehydrogenase

SEM

standard error of the mean

SNK

Student-Newman-Keuls

STAT3

signal transducer and activator of transcription 3

pSTAT3

phosphorylated STAT3

MFG-E8

milk fat globule-epidermal growth factor-factor VIII

rmMFG-E8

recombinant murine MFG-E8

IL

interleukin

PMA

phorbol 12-myristate 13-acetate

PMN

polymorphonuclear neutrophil

GM-CSF

granulocyte-macrophage colony-stimulating factor
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Figure 1. IL-17 expression in blood after sepsis and effect of rmMFG-E8

After 10 h of sepsis, serum was collected from sham, vehicle-, and rmMFG-E8-treated
animals. A total of 3 μl of serum from each group was analyzed via western blot. Ponceau
staining confirmed equal loading. Compared to the vehicle group, intrajugular treatment of
rmMFG-E8 at a dose of 20 μg/kg BW inhibited IL-17 protein levels in the plasma by 31%.
Sham, n=3 mice; vehicle-, and rmMFG-E8-treated, n=6 mice/group. Data are expressed as
mean ± SEM and compared by one-way ANOVA by SNK method (*p<0.05 vs. sham; #
p<0.05 vs. vehicle).
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Figure 2. Effect of rmMFG-E8 on IL-17 expression in the spleen

Author Manuscript

Spleen tissue was isolated from sham, vehicle- and rmMFG-E8-treated animals after 10 h of
sepsis. Extracted mRNA and protein were subjected to real-time PCR and western blot to
determine IL-17 expression at its transcriptional and translational levels, respectively.
Compared to the vehicle, intrajugular treatment of rmMFG-E8 at 20 μg/kg BW inhibited
IL-17 (A) mRNA, and (B) protein expression by 81% and 51%, respectively. Sham,
vehicle-, and rmMFG-E8-treated, n=4–8 mice/group. For both real-time PCR and western
blot, the results are normalized with β-actin as an internal control and equal loading control
for respective experiments. The results are expressed as fold induction in comparison with
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the sham. Data are expressed as mean ± SEM and compared by one-way ANOVA by SNK
method and Student’s t test (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 3. Treatment with recombinant mouse MFG-E8 attenuates organ injury

Serum was collected at 10 h after CLP from sham, vehicle-, and rmMFG-E8-treated (20
μg/kg BW) mice. Levels of (A) AST (B) ALT, and (C) LDH were measured and found to be
reduced in the treatment group. Sham, n=3 mice; vehicle-, and rmMFG-E8-treated, n=7
mice/group. Data are expressed as means ± SEM and compared by one-way ANOVA by
Dunn’s and SNK method, and Mann Whitney Rank Sum test (*p<0.05 vs. sham; # p<0.05
vs. vehicle).
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Figure 4. In vitro treatment of rmMFG-E8 in splenocytes decreases PMA/ionomycin-induced
IL-17 production
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Splenocytes were isolated from C57BL/6 mice and a total of 1.5 × 106 cells/ml in a 24-well
culture plate were pre-treated with rmMFG-E8 (500 ng/ml) for 90 min, followed by
stimulation with PMA (10 ng/ml) and ionomycin (1 μg/ml) for 5 h. mRNA was then
extracted for real-time PCR to quantify IL-17 expression. IL-17 mRNA expression is
significantly decreased by 49% with rmMFG-E8 treatment. The ratio obtained in the PBS
control was arbitrarily set to 1. The results are obtained from n=3 mice/group with 3
independent experiments. β-actin serves as an internal control for normalization of the
results. Data are expressed as mean ± SEM and compared by one-way ANOVA by SNK
method (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 5. In vitro stimulation with PMA/ionomycin shows increased IL-17 production in CD4 Tcells isolated from MFG-E8 deficient mice
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CD4 T-cells from 8–10 week-old male wt or mfge8−/− mice spleens were isolated by
negative selection. A total of 1.5 × 106 cells/ml isolated from wt or mfge8−/− mice in a 24well culture plate were stimulated by PMA (10 ng/ml) and ionomycin (1 μg/ml) for 5 h,
followed by the assessment of IL-17 in culture supernatants by ELISA. Cells from mfge8−/−
mice exhibited 4.7-fold upregulation of PMA/ionomycin-induced IL-17 production
compared to that of wt mice. The results are obtained from n=4 mice/group. Data are
expressed as mean ± SEM and compared by one-way ANOVA by SNK method and
Student’s t test (*p<0.05 vs. sham; # p<0.05 vs. vehicle).
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Figure 6. Treatment of rmMFG-E8 into the septic animals downregulates STAT3
phosphorylation in the spleen

(A) Vehicle or rmMFG-E8 (20 μg/kg BW) was injected intravenously into the CLP animals.
Following 10 h of CLP, spleen samples were harvested to analyze for phosphorylation of
STAT3 by western blot. Mice treated with rmMFG-E8 downregulated STAT3
phosphorylation in spleen tissue by 54%. (B) Sepsis was induced in C57BL/6 wt and
mfge8−/− mice by CLP and after 10 h spleen tissue was collected for western blot. Mfge8−/−
mice showed significantly increased levels of pSTAT3 by 25% compared to wt mice. The
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representative results for 6A are obtained from sham, n=5 mice; vehicle and rmMFG-E8
treatment, n=6–7 mice/group. The representative results for 6B are obtained from sham, n=3
mice; wt and mfge8−/−, n=5 mice/group. Results are normalized with β-actin as an equal
loading control and are expressed as fold induction in comparison with the sham. Data are
expressed as mean ± SEM and compared by one-way ANOVA by SNK method(*p<0.05 vs.
sham; # p<0.05 vs. vehicle).
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